Clinical Trial Update: Transarterial Chemoembolisation Plus Bevacizumab for Treatment of Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating transarterial chemoembolisation plus bevacizumab for hepatocellular carcinoma was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Bevacizumab (bevacizumab)

Snippet

Sponsor: Medical University of Vienna | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: TERMINATED